Seqster said today it will furnish its Seqster Research Portal (SRP) health data management platform to La Jolla Institute of Immunology (LJI) under a three-year licensing agreement and partnership whose value was not disclosed.
LJI plans to use Seqster’s SRP technology to connect patients, clinicians, and researchers in the development of personalized treatments for asthma, by studying longitudinal data for a 3-year period starting with 5000 participants.
The agreement is designed to support a $6.9 million asthma study funded by the NIHI’s National Heart, Lung and Blood Institute (NHLBI) that establishes one of only 10 PrecISE Network Clinical Centers nationwide. PrecISE stands for the Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network, a network of leading academic institutions and physician-scientists created to discover personalized treatments for patients with severe asthma.
LJI, founded in 1988, is an independent, nonprofit research organization dedicated to understanding the intricacies and power of the immune system to promote human health and prevent a wide range of diseases.
“We needed a scalable and robust platform that supports rapid person-centric data aggregation as well as real-time collection of longitudinal health records data to build this important and ambitious research cohort,” Stephen Wilson, Ph.D., Executive Vice President and Chief Operating Officer of LJI, said in a statement. “The Seqster Research Portal is the only platform that will allow our PrecISE study participants to instantly collect and share medical records, genomic and device data with our researchers from anywhere in the country in a secure and transparent way while maintaining data ownership.”
Seqster’s SRP is a software-as-a- service (SaaS) healthcare platform is designed to improve the efficiency of healthcare organizations by integrating comprehensive electronic medical records (EHR), individual genomic profiles (DNA), and personal health device data, such as from wearables of fitness devices. The portal is intended to streamline the study recruitment and consent process, directly importing Real-World Data (RWD) and Real-World Evidence (RWE) with chain of custody.
“It is exciting that our SRP platform is providing the technology backbone for such an innovative clinical study infrastructure that will yield important efficacy and safety data on novel asthma interventions,” Ardy Arianpour, CEO and Co-Founder of Seqster, said in a statement. “A commitment of this magnitude from such a prestigious research institute as LJI is further validation that Seqster’s person-centric approach to health data interoperability brings together patients, clinicians and researchers to accelerate discoveries, and we’re thrilled we can help support it.”
Headquartered in San Diego, privately-held Seqster launched its platform in 2018 after raising $4 million in seed financing. Also last year, Seqster integrated its health data management platform with the MyGeneRank app of Scripps Research Translational Institute (SRTI), through a collaboration designed to promote better healthcare decisions by app users through tracking of medications and lifestyle modifications. MyGeneRank is designed to allow individuals with genetic data from 23andMe to obtain an estimated genetic risk score for coronary artery disease.
Seqster oversees a platform that now connects users to more than 3000 healthcare providers and over 100,000 hospitals and clinics nationwide.